Paradigm signs contract with Stratose for personalized medicine service

Paradigm, a molecular information and Next Generation Sequencing corporation specializing in providing cancer testing for patients with cancer, announced that it has entered into a contractual agreement with Stratose for coverage of PCDx.

PCDx is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patients tumor's DNA, RNA & Protein.

Dr. Robert Penny, MD, PhD, CEO of Paradigm, noted, "Through this contract, millions of Stratose client members and their treating clinicians will have access to this important oncology service and make possible more informed and individually tailored treatment strategies."

To continue reading this article…

Start your monthly or annual subscription to HIT Leaders & News today!

A monthly Standard subscription to all our regular news articles costs only $12.00 per month, or $144.00 for an annual Standard subscription.

Already a subscriber? Log in


molecular information, Next Generation Sequencing, Paradigm, PCDx, Stratose


Please follow and ‘Like’ us


©2021 HIT Leaders and News, a GO Digital Media publication. All rights reserved.